BVT:JSEBidvest Group Limited Analysis
Data as of 2026-03-14 - not real-time
ZAC 22,850.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
The Bidvest Group trades at ZAc 22,850, which sits about 15% above its DCF‑derived fair value of ZAc 19,889, signaling a potential overvaluation despite a solid dividend yield of 4.33% and a modest payout ratio of 52%. Technical gauges show the stock is below its 20‑day (ZAc 24,223) and 50‑day (ZAc 24,227) moving averages, with an RSI of 34.6 indicating oversold conditions, while a bearish MACD histogram reinforces short‑term downside pressure. Nevertheless, the company’s low beta of 0.37 and increasing volume suggest limited market‑wide volatility, and its diversified industrial footprint provides a stable earnings base.
Fundamentally, Bidvest delivers a PE of 12.97 versus an industry average of 29.1, a healthy ROE of 15.4%, and free cash flow that comfortably covers its dividend. The combination of a strong dividend, low valuation multiples, and resilient cash generation supports a value‑oriented investment case, though the price premium to intrinsic value warrants caution.
Fundamentally, Bidvest delivers a PE of 12.97 versus an industry average of 29.1, a healthy ROE of 15.4%, and free cash flow that comfortably covers its dividend. The combination of a strong dividend, low valuation multiples, and resilient cash generation supports a value‑oriented investment case, though the price premium to intrinsic value warrants caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI near oversold territory suggesting limited upside
- Bearish MACD histogram indicating continued pressure
- Price trading below short‑term moving averages
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- PE well below industry average offering valuation cushion
- Sustainable dividend yield of 4.33% with healthy cash flow
- Low beta reducing exposure to broader market swings
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Diversified conglomerate model providing resilient earnings
- Strong ROE and free cash flow supporting dividend continuity
- Potential price correction toward DCF fair value offering upside
Key Metrics & Analysis
Financial Health
Revenue Growth3.70%
Profit Margin4.72%
P/E Ratio13.0
ROE15.38%
ROA6.10%
Debt/Equity102.11
P/B Ratio197.9
Op. Cash FlowZAC11.1B
Free Cash FlowZAC6.7B
Industry P/E29.1
Technical Analysis
TrendNeutral
RSI34.6
SupportZAC 20,650.00
ResistanceZAC 26,000.00
MA 20ZAC 24,223.65
MA 50ZAC 24,226.68
MA 200ZAC 23,263.77
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair ValueZAC 19,889.81
Target PriceZAC 29,955.83
Upside/Downside31.10%
GradeOvervalued
TypeValue
Dividend Yield4.33%
Risk Assessment
Beta0.37
Volatility25.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.